
Index

- Achondroplasia (dwarfism), 7, 30, 31
 Ad hoc studies, epidemiologic, 14, 103, 104, 107
 Adenine (A), 23, 24, 27, 64, 66
 Adenosine deaminase deficiency, 105
 Agarose gel electrophoresis, 59, 60, 61, 63, 68
 Agency for Toxic Substances and Disease Registry (ATSDR), 18-19
 Agent Orange, 18
 Alanine, 27
 ALARA principle, 114
 Alkylating agents, 93-94
 Alleles, 27, 44, 77, 82
 Alpha-globin chain, 47
 Alpha-thalassemia, 29
 American Society of Human Genetics, 19
 Ames test, 15, 118
 Amino acids, 9, 25-27, 29, 44, 46, 47, 49, 57, 58, 78; *see also specific amino acids*
 Amniocentesis, 41
 Animals, mutation studies in, 3-5, 6-7, 19, 48, 78, 81-87, 91-100, 117-118
 Aniridia, 7
 Antibodies, in somatic mutation studies, 77-78
 Apert's syndrome, 31
 Arginine, 27
 Asparagine, 27
 Aspartic acid, 27
 Atomic Bomb Casualty Commission, 48
 Atomic bomb survivors, effects of radiation on, 9-10, 32, 48-50, 77, 86, 106, 108
 Atomic Energy Act, 114
 Atomic Energy Commission (AEC), 82, 114
 Autoradiographic assay, in somatic mutation studies, 74-75
 Autoradiography, 56, 59, 61, 64, 65, 68, 74-75
 Autosomes, 27, 38, 42, 44, 46, 49

 Bacteria, 81, 91, 92, 94, 116, 117, 118
 Benzo[a]pyrene, 97
 Beta-globin chain, 47, 77
 Biochemical analyses, 37, 44-48, 49-50, 51, 52
 Biologic extrapolation, *see* Extrapolation, qualitative
 Biological effects of ionizing radiation, 113
 Biological samples, banking of, 17-18
 Blood cells, somatic mutation studies on, 73-78
 Blood proteins
 detection of variants in, 44-48, 49-50
 electrophoretic analysis of, **8-9**, 10, **37**, **44-46**, **50**, **51**, **83**
 molecular analysis of, 46-48
 see also Enzymes; Hemoglobin proteins

 Cancer, 3, 7, 9, 15, 31-32, 38, 50, 73, 77, 104-105, 108-109, 117
 Cancer registries, 105, 109
 Case-control studies, in epidemiologic testing, 107
 Cells, *see* Blood cells; Chorionic villi cells; Germ cells; Red blood cells; Somatic cells; Stem cells; TG⁺ cells; White blood cells
 Centers for Disease Control, 18
 Chemicals
 denaturing, 12, 59, 61
 effects on DNA, 23, 59, 81
 effects on germinal mutations, 7, 9
 effects on heritable mutations, 6-7
 effects on somatic mutations, 7, 74-78
 in extrapolation models, 93-97, 100
 as mutagenic agents, 6-7, 9, 32, 48, 91-97, 106
 "standards" for, 17
 Chemotherapy, 108
 Children, genetic diseases in, 7-8, 30-32, 37, 38-40, 47-48, 49/ 50, 109, 110
 Chorionic villi cells, 41
 Chromosomes
 abnormal at birth, 41-43
 banding methods, 8, 28, 41, 42, 43, 50
 biochemical analyses of, 49-50
 cytogenetic analysis of, 37, 40-43, 49, 52, 55, 98
 DNA and, 23-25, 27-28, 41, 43
 health effects of abnormal, 40-43, 49
 mutations in, 5, 6, 8, 9, 13, 29-30, 31, 32, 40-43, 49, 51, 68, 82, 92, 95
 numerical abnormalities, 8, 29-30, 31, 41, 49, 116
 pulsed field gel electrophoresis and, 68
 staining methods, 8, 28, 41, 42, 43, 50
 structural abnormalities, 8, 29, 31, 41, 49
 studies in mice, 82
 surveillance of abnormal, 105
 translation of, 30, 82
 Chronic hemolytic anemia, 46, 47
 Clonal assay, in somatic mutation studies, 75
 Cloning, 58-59, 60, 64-65, 75
 Codons, 6, 25-27, 29
 Cohort studies, in epidemiologic testing, 107, 109
 Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA), 3, 15, 114
 Congenital hypothyroidism, 105
 Consumer Product Safety Act, 114
 Consumer Product Safety Commission, 114
 Cyanosis, 47
 Cyclophosphamide, 97
 Cysteine, 27

- Cytogenetic analysis, of chromosome abnormalities, 37, 40-43, 49, 52, 55, 98
- Cytosine (C), 23, 24, 27, 64, 66
- Cytotoxic drugs, 108
- Deoxyribonucleic acid (DNA)
- chromosomes and, 23-25, 27-28, 41, 43
 - current methods for studying, 6-10
 - denaturing of, 11-12, 59-64
 - double helix, 24, 25, 27
 - double-stranded, 12-13, 23, 59-68
 - EPA guidelines and, 116
 - extrapolation studies and, 91-100
 - Federal expenditures on research, 121-122
 - function and organization of, 23-28
 - genetic nature of, 3, 4, 5-6
 - genomic, 6, 11, 55, 57-68
 - heteroduplexes, 12, 55, 61, 62, 63, 64-65, 67
 - homoduplexes, 61, 63, 67
 - hybridization, 66-67
 - nontranscribed, 45
 - nucleotide chains in, 23-25
 - organizational hierarchy of, 6
 - replication of, 23-25, 74
 - sequencing, 23-25, 55, 57-58, 60, 61-64, 66-67, 104
 - single-stranded, 12-13, 59-68
 - structure of, 23-25, 81
 - use of new technologies in examining, 10-14, 17, 55-69, 74-76
- Department of Defense, 114
- Department of Energy (DOE), 16, 17, 19, 55, 114, 122
- Department of Transportation, 114
- Diabetes, 3
- Dioxin, 106
- Disease registries, 104-106, 107
- Diseases
- dominant, 44
 - environmental factors in, 31
 - genetic, 3, 5, 7-8, 9, 30-33, 37, 38-40, 42, 44-45, 47-48, 49, 50, 93, 94, 103-110, 108-109, 110, 115
 - "multifactorial," 31
 - recessive, 44
 - see also Sentinel phenotypes and *specific diseases*
- DNA-RNA heteroduplex analysis, 12, 64-65
- Dominant lethal test, 81-82
- Dominant mutation tests, 83
- Dose-response relationships, in quantitative extrapolation studies, 97-99
- Down syndrome, 3, 8, 30, 31, 42
- Drosophila, 48, 81, 82, 96, 116, 117
- Duchenne muscular dystrophy, 3, 30
- Electrophoresis, 8-9, 10, 11-12, 13, 37, 44-46, 49, 50, 51, 55, 68, 83, 84
- see also Gel electrophoresis and *specific types of gel electrophoresis*
- Embryos, in rodent tests, 81-82
- Endonucleases, restriction, use in detecting mutations, 11
- Environmental Protection Agency (EPA), 15, 16, 19, 114, 115, 116, 117
- Enzymes
- biochemical analyses of, 49-50
 - HPRT, 74
 - kinetic studies of, deficiency variants, 44, 45-46
 - quantitative studies of deficiency variants, 45-46, 83, 84
 - restriction, 11, 13, 58-64, 66, 67, 68, 75
 - RNaseA, 12
 - role in protein synthesis, 25-27
 - somatic mutation studies on, 73
- Epidemiologic studies, 9-10, 14, 18, 49, 103-110
- Epstein-Barr virus, 104
- Escherichia coli*, 58, 60
- Ethylene dibromide (EDB), 115, 117
- Ethylene oxide (EtO), 115, 117
- Ethyl nitrosourea (ENU), in quantitative extrapolation studies, 97, 98-99
- Eukaryotes, 92, 94, 95, 116
- Exposure registries, 106, 107
- Extrapolation
- aims of, 91-92
 - from animal to human data, **86-87**
 - defined, 14-15
 - limits of, 99-100
 - qualitative, 15, 91, 94-97, 99-100
 - quantitative, 15, 91, 97-100, 115, 117
 - theoretical models for, 15, 93-94
- Federal Food, Drug, and Cosmetics Act, 114
- Federal Insecticide, Fungicide, and Rodenticide Act, 115
- Federal Radiation Council (FRC), 113, 114
- Fetuses, chromosome abnormalities in, 40, 42, 82
- Fluorochrome, 77
- Food and Drug Administration (FDA), 19, 114
- Fruit flies, see *Drosophila*
- Fungi, 92
- Galactosemia, 105
- Gamma radiation, 97
- Gel electrophoresis, 11-12, 13, 55, 56, 58, 59, 65
- see also Agarose gel electrophoresis; One-dimensional denaturing gradient gel electrophoresis; Pulsed field gel electrophoresis; Two-dimensional denaturing

- gradient gel electrophoresis; Two-dimensional polyacrylamide gel electrophoresis
- Genes
- dominant, 27, 44, 51
 - globin, 29, 46, 47-48, 55
 - hprt*, 55, 74-76
 - mutations in, 5, 6-7, 29, 38-40, 42-43, 44, 47-48, 50, 51, 55, 57-68, 74-76, 92, 95
 - recessive, 27, 44
- Genomes and genomic sequencing, 6, 11, 57-58, 66-67, 68
- Germ cells, 6, 7, 9, 13, 27, 30, 31, 37, 38, 39, 48, 49, 80-84, 91-100, 108, 115-116, 117; see also Germinal mutations
- Germinal mutations
- in cells, 7
 - defined, 6
 - electrophoretic studies on, 51
 - new, 37-38
 - radiation-induced, 9-10, 48-49
 - relationship to somatic mutations, 73
 - see also Mutations
- Glossary of Acronyms and Terms, vii-xii
- Glutamic acid, 26, 27, 29
- Glutamine, 27
- Glycine, 27
- Glycophorin A, 76-77
- Glycophorin assay, in somatic mutation studies, 76-77
- Guanine (G), 23, 24, 27, 64, 66
- "Guidelines for Mutagenicity Risk Assessment," 116
- Health effects
- of chromosome abnormalities, 40-43
 - of mutations, 4, 30-32, 108-109
 - see also Children; Diseases; Humans; Infants
- Heart disease, 3, 25, 32
- Hemoglobin A (HbA), 46
- Hemoglobin assays, in somatic mutation studies, 77-78
- Hemoglobin C, 77
- Hemoglobin M (HbM), molecular analysis of, 44, 46-48, 51
- Hemoglobin S, 77
- Hemoglobins, unstable, molecular analysis of, 44, 46-48, 51
- Hemophilia, 3
- Heritable mutations
- chemicals and, 6-7, 9, 32, 48, 91-97
 - defined, 6
 - detection and measurement of, 11-13
 - epidemiologic studies in, 9-10, 14, 18, 49, 103-110
 - estimating effects in humans from animal data, 86-87
 - extrapolation of data to predict risk in humans, 91-100
 - factors that influence induced rates in mice, 84-86
 - health effects of, 30-32, 108-109
 - induced by chemicals, 6-7
 - kinds and rates of, in humans, 32-33, 37-52
 - laboratory studies on, 81-87
 - new technologies and, 3, 10-14, 55-69
 - rodent tests for, 81-84
 - spontaneous, studies in humans, 7-10
 - see also Mutations
- Heritable translocation tests (HTTs), 82, 94-96, 98
- Heteroduplexes, 12, 55, 61, 62, 63, 64-65, 67
- Heterozygotes, 44, 45, 77, 82
- Histidine, 27, 47
- Histidinemia, 105
- Hodgkin's disease, 108
- Homocystinuria, 105
- Homoduplexes, 61, 63, 67
- Homologous sequences, 64
- Homozygotes, 44, 82
- hprt*, 55, 74-76
- Humans
- animal studies and, 84-87
 - epidemiologic studies in, 9-10, 14, 18, 49, 103-110
 - Federal expenditures on mutation research in, 121-122
 - frequencies of *hprt* T-lymphocytes in, 76
 - health effects of mutations in, 30-32, 108-109
 - kinds and effects of mutations in, 4, 5-6, 29-32
 - kinds and rates of heritable mutations in, 32-33, 37-52
 - mutagenic risk predictions by extrapolation, 91-100
 - mutation studies in, 3-4, 7-14, 19, 44-52, 55-69, 73-78
 - new technologies for detecting mutations in, 10-14, 55-69, 73-78
 - persistence of new mutations in, 32-33, 37
 - sentinel phenotypes in 7-8, 37, 38-40, 45, 50, 51, 52, 55, 105, 106, 109
 - spontaneous mutation rates in, 32-33, 51
 - see also Children; Diseases; Infants
- Huntington disease, 31
- Hypoxanthineguanine phosphoribosyl transferase (HPRT), 74
- Infants, genetic diseases in, 7-8, 30-32, 37, 38-40, 42, 44-45, 49, 50, 109
- Insects, 91, 92, 116

International Commission for Protection Against Environmental Mutagens and Carcinogens (ICPEMC), 55

International Commission on Radiological Protection (ICRP), 113, 114

International dioxin registry, 106

Isoleucine, 27

Karyotypes, 28, 41, 42

Kinetic studies, of enzyme deficiency variants, 45-46

Laboratory studies, of heritable mutation rates, 81-87; see *also* Animals

Lambda (virus), 59, 60

Leucine, 27

Leukemia, 9, 32, 109

Lysine, 26, 27

Maple syrup urine disease, 105

Marfan's syndrome, 31, 109

Measurement techniques, validation of, 104

Messenger RNA (mRNA), 25, 26

Methemoglobinemia, 47

Methemoglobinemic cyanosis, 46

Methionine, 27

Methyl isocyanate, 106

Mice

effects of radiation on, 82-86, 97

in extrapolation tests, 93, 96

factors affecting mutations in, 84-86

heritable mutation tests in, 82-84

mutation effects in females, 85-86

mutation effects in males, 84-85

spermatogonial studies in, 84-85, 97-98

unscheduled DNA synthesis in spermatids of, 97-98

Mine Safety and Health Administration (MSHA), 114

Monitoring, in epidemiologic testing, 14, 103-104, 106, 107

Mortality and morbidity, 31, 41, 49, 82

Mouse spot test, 96

Mutagenicity assays, 91-100; see *also* Mutations *and specific tests for mutagenicity*

Mutants, in somatic mutation studies, 74-78; see *also* Mutations

Mutations

animal studies, 3-5, 6-7, 19, 48, 78, 81-87, 117-118

at birth, 41

in chromosomes, 5, 6, 7, 8, 9, 13, 29-30, 31, 32, 40-43, 49, 51, 68, 82, 92

at conception, 41

current methods for studying, 6-10, 37-52

dominant, 32, 38, 44

environmental factors in, 3, 4, 37, 73, 96, 106, 108-109

Federal expenditures on research, 15, 18, 117, 121-122

in genes, 5, 6-7, 29, 38-40, 42-43, 44, 47-48, 50, 51, 55, 57-68, 74-76, 92, 95

genetic inheritance and, 23-33

germinal, see Germinal mutations

health effects of 4, 30-32, 108-109

heritable, see Heritable mutations

human studies, 3-4, 7-14, 19, 44-52, 55-69, 73-78, 103-110

kinds of, and effects in humans, 4, 5-6, 29-32, 55

new, persistence of in humans, 32-33, 37, 41

new technologies for detecting in humans, 10-19, 55-69

options for research on, 16-19

in proteins, 3, 8-9, 25-27, 29, 44-48, 49, 56-57

recessive, 32, 33

regulatory considerations, 15, 17, 113-118

somatic, see Somatic mutations

spontaneous, 5, 7, 32-33, 51, 83

test methods for research in, 14-16

X-linked (sex-linked), 32, 37, 38

National Cancer Institute, 104

National Center for Toxicological Research, 19

National Council on Radiation Protection and Measurements (NCRP), 113, 114

National Environmental Protection Act of 1970, 114

National Institutes of Health (NIH), 122

National Research Council (NRC), 32-33

National Toxicology Program (NTP), 19

Neuroblastoma, 109

Nuclear Regulatory Commission (NRC), 106, 108, 114

Nucleotides and nucleotide sequencing, 5-6, 8, 11, 12, 23-25, 29, 44, 46, 47, 57-58, 59, 61, 66, 68, 93

Occupational Safety and Health Act, 114, 115

Occupational Safety and Health Administration, 114, 115

Office of Technology Assessment (OTA), 4, 15, 121

One-dimensional denaturing gradient gel electrophoresis, 55, 59-61, 63

Oocytes, in mice, 85-86

Osteogenesis imperfect, 30

- Parallelogram, as extrapolation model, 93, 97, 117
 Peripheral blood lymphocytes (PBLs), 97
 PFGE, see Pulsed field gel electrophoresis
 Phenotypic data
 limitations of, 40, 45
 mutation rates estimated from, 39-40
 surveillance of, 38-40
 see also Sentinel phenotypes
 Phenylalanine, 26, 27
 Phenylketonuria (PKU), 45, 105
 Polyacrylamide, use in protein separation, 5.5, 56-57
 Polymorphisms, 58-59, 64
 Polypeptide chain, 26, 37, 46; see also Proteins
 Prokaryotes, 94, 95
 Proline, 27
 Proteins
 biochemical analysis of, 37, 44-48, 49-50, 51, 52
 DNA and, 23-27, 45, 46, 50, 57
 mutations in, 3, 8-9, 25-27, 29, 44-48, 49, 56-57
 one-dimensional separation of, 8-9, 44-45, 49, 56
 synthesis of, 25-27
 variant, mutation studies on, 8-9, 44-50, 55, 56-57, 73-74
 two-dimensional separation of, 9, 56-57
 see also Amino acids; Blood proteins; Enzymes; Hemoglobins, Nucleotides and nucleotide sequencing
 Public Health Service, 18
 Pulsed field gel electrophoresis (PFGE), 13, 55, 68

 Qualitative studies, 15, 91, 94-97, 99-100
 Quantitative studies, 15, 45-46, 55, 91, 97-100, 115, 117

 Radiation
 effects on atomic bomb survivors, 9-10, 32, 48-50, 77, 86, 106, 108
 effects on DNA, 23
 effects on fruit flies, 82
 effects on human germ cells, 9
 effects on mice, 82-86, 97
 effects on pregnant women, 9
 effects on U.S. citizens, 86-87, 106
 in extrapolation studies, 97-100
 in Marshall Islands populations test, 50
 in somatic mutation studies, 74
 mutagenic effects of, 73
 U.S. Government efforts to protect humans from, 113-114
 Radiation Effects Research Foundation, 16, 48, 104
 Radioactive thymidine, 74
 Red blood cells, somatic mutation studies on, 73, 76-78

 Regulatory considerations
 definition of germ-cell mutagen, 115-117
 mutagenicity and carcinogenicity, 117-118
 new methods for measuring mutation rates, 118
 protection against agents other than radiation, 114
 quantitative extrapolation, 117
 radiation protection, 113-114
 role of U.S. Government, 15, 17, 113-118
 Research and public policy, use of new technologies in, 14-16
 Restriction fragment length polymorphisms (RFLPs), 55, 58-59, 60
 Retinoblastoma, 7, 31, 109
 Ribonuclease A (RNaseA), 64, 65
 Ribonuclease cleavage of mismatches in RNA/DNA heteroduplexes, 12, 55, 64-65
 Ribonucleic acid (RNA)
 heteroduplexes, 55, 64-65
 role in protein synthesis, 26, 45
 Risk assessment, EPA guidelines for, 116
 RNA, transcribed, 45
 RNA/DNA heteroduplexes, ribonuclease cleavage of mismatches in, 12, 55, 64-65
 Rodents, heritable mutation tests in, 81-84

 Salmonella, 118
 Sentinel phenotypes, 7-8, 37, 38-40, 45, 50, 51, 52, 55, 105, 106, 109; see also Phenotypic data
 Serine, 27
 Sickle-cell anemia, 105
 Sister-chromatid exchange (SCE), 99, 116
 6-TG, use in somatic mutation studies, 74-75
 Somatic cells, 7, 13-14, 27, 31-32, 73, 91-100, 115, 116, 117; see *also* Somatic mutations
 Somatic mutations
 defined, 6
 detection and measurement of, 4, 13-14
 effects of, 31-32
 new methods for measuring in humans, 73-78
 see *also* Mutations
 Specific locus tests (SLTs), 50, 82-83, 85, 94-96, 97-98, 116
 Spermatogonial studies in mice, 84-85, 97-98
 Spontaneous mutation rates, 5, 7, 32-33, 51, 83
 Squirrel monkeys, 85
 Stem cells, in mice, 84, 85
 Subtractive hybridization, 12, 55, 66-67
 "Superfund," 18, 114
 Surveillance, in epidemiologic testing, 14, 103, 104-106, 107

 T-lymphocytes, 74-76
 Technologies, new

- for detecting mutations in humans, 10-19, 55-69
- development of, and research on, 16-19
- and heritable mutations, 3, 10-14, 55-69
- use in research and public policy, 14-16
- Tester mice, 82-83
- Thioguanine resistant (TG^r) cells, 99
- Threonine, 27
- Thymine (T), 23, 24, 27, 64, 66
- Toxic Control Substances Act of 1976 (TSCA), 3, 15, 114, 118
- Transfer RNA (tRNA), 26
- Tryptophan, 27
- Turner's syndrome, 30, 42
- Two-dimensional denaturing gradient gel electrophoresis, 55, 61-64
- Two-dimensional polyacrylamide gel electrophoresis, 56-57
- 2DGGE, *see* Two-dimensional denaturing gradient gel electrophoresis
- 2-D PAGE, *see* Two-dimensional polyacrylamide gel electrophoresis
- Tyrosine, 27, 47
- United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), 113-114
- U.S. Congress, 4, 15, 16-19, 113; *see also* U.S. Government
- U.S. Government
 - efforts to protect humans from radiation, 113-114
 - expenditures on mutation research, 15, 18, 117, 121-122
 - regulation by, 15, 17, 113-118
 - role in mutation research, 4, 5, 15, 16-19, 113-118
 - see also*** U.S. Congress and ***specific Federal agencies***
- Validation of measurement techniques in epidemiologic testing, 104
- Valine, 26, 27, 29
- Viruses, effects on DNA, 23
- White blood cells, somatic mutation studies on, 73, 74-76
- Whole mammal tests, *see* Specific locus tests; Heritable translocation tests
- Wild-type mice, 82-83
- Wilms' tumor, 7, 31, 109
- Xeroderma pigmentosum, 32
- Yeast, 81, 92, 116

O

LIBRARY
 OFFICE OF TECHNOLOGY ASSESSMENT
 CONGRESS OF THE UNITED STATES
 WASHINGTON, D.C. 20510